A Phase I/II Study of Lenalidomide and Obinutuzumab With CHOP for Diffuse Large B Cell Lymphoma
Status:
Active, not recruiting
Trial end date:
2021-11-01
Target enrollment:
Participant gender:
Summary
There are 2 parts to this study: Part 1 (dose de-escalation) and Part 2 (dose expansion).
The goal of Part 1 of this clinical research study is to find the highest tolerable dose of
lenalidomide in combination with obinutuzumab and CHOP (cyclophosphamide, doxorubicin,
vincristine, and prednisone) that can be given to patients with diffuse large B cell
lymphoma.
The goal of Part 2 of this clinical research study is learn if the dose of lenalidomide found
in Part 1 can help to control the disease.
The safety of this drug combination will be studied in both parts.